Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial

Combining atezolizumab with bevacizumab and chemotherapy did not significantly improve OS or PFS in patients with recurrent ovarian cancer ineligible for platinum. The safety profile was as expected from previous experience with these drugs.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-12-03
DOI
https://doi.org/10.1200/jco-25-01210
Citations
1
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
1.70
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial

Annette Hasenburg, Goda Jonuškienė, Lydia Gaba, Frederik Marmé et al.
1 citations
Journal of Clinical Oncology
Ovarian cancer diagnosis and treatment
1.70
article

Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial

Annette Hasenburg, Goda Jonuškienė, Lydia Gaba, Frederik Marmé, Florence Joly, Carmen García-Durán, Nikolaus de Gregorio, Florian Heitz, Alexander Burges, Christian Marth, B. Pardo, Pauline Wimberger, Ignacio Romero, Ahmed El‐Balat, José Alejandro Pérez Fidalgo, Frédèric Selle, Kristina Lindemann, Klaus Pietzner, Patricia Pautier, Barbara Schmalfeldt, Isabelle Laure Ray-Coquard, Philipp Harter, Andrés Redondo, Michel Fabbro, Christian Kurzeder, Alexander Reuß, Els Van Nieuwenhuysen, Philippe Follana, Charlotte Béllier
article en
1 citations

Abstract

Combining atezolizumab with bevacizumab and chemotherapy did not significantly improve OS or PFS in patients with recurrent ovarian cancer ineligible for platinum. The safety profile was as expected from previous experience with these drugs.

Journal of Clinical OncologyVol. 44(2)
Université Claude Bernard Lyon 1 (FR), Goethe University Frankfurt (DE), Oslo University Hospital (NO), Saab (Switzerland) (CH), Innsbruck Medical University (AT), Universität Hamburg (DE), Philipps University of Marburg (DE), University of Oslo (NO), Universität Innsbruck (AT), Johannes Gutenberg University Mainz (DE), Heidelberg University (DE), Hospital Universitario La Paz (ES), Institut Gustave Roussy (FR), University Hospital Heidelberg (DE), University Hospital of Basel (CH), LMU Klinikum (DE), Humboldt-Universität zu Berlin (DE), Nordic Society of Gynecologic Oncology (DK), Düsseldorf University Hospital (DE), Klinik für Frauenheilkunde (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe (DE), University Hospital of Zurich (CH), Fundación Instituto Valenciano de Oncología (ES), Centre Léon Bérard (FR), Institut Català d'Oncologia (ES), University Medical Center Hamburg-Eppendorf (DE), Groupe Hospitalier Diaconesses Croix Saint-Simon (FR), Hospital Clínic de Barcelona (ES), Centre François Baclesse (FR), Vall d'Hebron Hospital Universitari (ES), Centre Oscar Lambret (FR), Arcagy Gineco (FR), Duran i Reynals Hospital (ES), AGO Austria (AT), Kliniken Essen-Mitte (DE), Klinik und Poliklinik für Neurologie (DE), Centre Antoine Lacassagne (FR), Spanish Ovarian Cancer Research Group (ES), University Hospital Ulm (DE), SLK-Kliniken Heilbronn (DE), University Medical Centre Mannheim (DE), INCLIVA Health Research Institute (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), Vilnius University Hospital Santariskiu Klinikos (LT), University Hospital Carl Gustav Carus (DE), Vall d'Hebron Institute of Oncology (ES), Heinrich Heine University Düsseldorf (DE), Ludwig-Maximilians-Universität München (DE), KU Leuven (BE)
Openalex Percentile: Top 11%
Ovarian cancer diagnosis and treatment
1.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.